Molecular inhibitor against periodontitis
Innovation in the dental sector
PerioTrap Pharmaceuticals GmbH is developing a selective active ingredient against a target enzyme found exclusively in the main pathogens causing periodontitis. Selective targeting and a novel application mechanism for targeted use at the site of infection can eliminate the need for conventional broad-spectrum antibiotics and minimize the impact on the natural oral flora. Chronic disease states are thus overcome and side effects reduced.